Skip to Main Content

Metastatic Surgery

September 30, 2025

What is the rationale for cytoreductive radical prostatectomy trial?

ID
13463

Transcript

  • 00:02For these patients who have
  • 00:04metastatic prostate cancer, then the
  • 00:06current standard of care is
  • 00:07systemic therapy, or some so
  • 00:09called the hormonal therapy,
  • 00:11plus or minus chemotherapy.
  • 00:13And again,
  • 00:15that and those
  • 00:16agents,
  • 00:17are given that results of
  • 00:19about a three year survival,
  • 00:20median survival for these patients
  • 00:22right now. So,
  • 00:24what I'm trying to do
  • 00:25right now in our study
  • 00:27is, is that does a,
  • 00:29site reduction or removing
  • 00:32the local disease,
  • 00:34help treat systemic disease? So
  • 00:36what I mean by that
  • 00:37is, is that, if we
  • 00:39take out
  • 00:40the site where the cancer
  • 00:41came from, then will the
  • 00:43hormonal therapy, will the chemotherapy
  • 00:45be more effective
  • 00:47against prostate cancer that has
  • 00:49gone to the bones, to
  • 00:50the lymph nodes, or liver,
  • 00:51or other part of the
  • 00:52body?